Abstract
RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Volume: 9 Issue: 3
Author(s): Gabriel Courties, Jessy Presumey, Isabelle Duroux-Richard, Christian Jorgensen and Florence Apparailly
Affiliation:
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Abstract: RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Export Options
About this article
Cite this article as:
Courties Gabriel, Presumey Jessy, Duroux-Richard Isabelle, Jorgensen Christian and Apparailly Florence, Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (3) . https://dx.doi.org/10.2174/1871523011009030251
DOI https://dx.doi.org/10.2174/1871523011009030251 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification and Validation of Novel Drug Targets in Tuberculosis
Current Pharmaceutical Design Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Translational Imaging of Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Circulating Osteoclast Precursors: A Mechanism and a Marker of Erosive Arthritis
Current Rheumatology Reviews Involvement of Coagulation and Hemostasis in Inflammatory Bowel Diseases
Current Vascular Pharmacology Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses
Current Pharmacogenomics Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Network Systems Underlying Traditional Chinese Medicine Syndrome and Herb Formula
Current Bioinformatics Hyperuricemia and Coronary Artery Disease
Current Rheumatology Reviews Potential Role of Calcium/Calmodulin-dependent Protein Kinase II to Angiogenesis Mediated Pathological Changes Seen in Osteoarthritis
Current Angiogenesis (Discontinued) Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry Molecular Characterization of the T Cell Repertoire Using Immuno-scope Analysis and its Possible Implementation in Clinical Practice
Current Molecular Medicine Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options
Current Topics in Medicinal Chemistry Fumagillin and Structurally Related Molecules as Source of New Drugs
Mini-Reviews in Organic Chemistry Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Osseotypes and Spondyloarthropathy Exposed
Current Rheumatology Reviews Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design Statin Treatment and Carotid Plaque Composition: A Review of Clinical Studies
Current Vascular Pharmacology